SARS-CoV-2 Infection in Patients with Extrapulmonary Tuberculosis
Author Information
Author(s): Mihuta Camil, Socaci Adriana, Hogea Patricia, Tudorache Emanuela, Mihuta Monica Simina, Oancea Cristian
Primary Institution: Victor Babes University of Medicine and Pharmacy, Timisoara, Romania
Hypothesis
How does SARS-CoV-2 infection impact patients with extrapulmonary tuberculosis compared to those with SARS-CoV-2 infection alone?
Conclusion
Coinfection with extraPTB and SARS-CoV-2 is associated with younger age and heightened systemic inflammation but does not significantly increase mortality risk compared to SARS-CoV-2 alone.
Supporting Evidence
- The coinfected group was younger, with 65% under 40 years.
- Coinfected patients had significantly higher IL-6, PCT, and transaminase levels.
- Non-fatal outcomes were more frequent in the coinfection group, with only one fatal outcome compared to 17 in the SARS-CoV-2-only group.
Takeaway
This study found that younger people with both SARS-CoV-2 and extrapulmonary tuberculosis have more inflammation but don't get sicker than those with just COVID-19.
Methodology
This retrospective, cross-sectional study included 123 patients hospitalized from March 2020 to March 2022, comparing 23 coinfected patients with 100 age-matched SARS-CoV-2-only patients.
Potential Biases
The retrospective nature of the study may introduce bias in data collection and interpretation.
Limitations
The small sample size of the coinfected group may limit the generalizability of the findings.
Participant Demographics
Patients aged 19–91 years, with 65% of the coinfected group under 40 years old.
Statistical Information
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website